JP Patent

JP5702929B2 — 認識機能障害(cognitiveimpairment)を治療するための、組み合わされたセロトニン再取り込み、5−HT3および5−HT1A活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)−フェニル]ピペラジン

Assigned to ハー・ルンドベック・アクチエゼルスカベット · Expires 2015-04-15 · 11y expired

What this patent protects

Patent listed against vortioxetine-hydrobromide.

Drugs covered by this patent

Patent Metadata

Patent number
JP5702929B2
Jurisdiction
JP
Classification
Expires
2015-04-15
Drug substance claim
No
Drug product claim
No
Assignee
ハー・ルンドベック・アクチエゼルスカベット
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.